Please login to the form below

Not currently logged in
Email:
Password:

Novo Nordisk says diabetes drug candidate successful in phase III trials

Danish pharmaceutical company Novo Nordisk has revealed that its diabetes drug candidate liraglutide has shown positive results in two phase III clinical trials.

Danish pharmaceutical company Novo Nordisk has revealed that its diabetes drug candidate liraglutide has shown positive results in two phase III clinical trials.

The trials, which are the second and third in a series of five phase three studies in the group's ongoing LEAD programme, showed that the compound improved glucose control and lowered the body weight of the participants.

Liraglutide is a long-acting analogue of the naturally occurring hormone, Glucagon-Like Peptide-1 (GLP-1), which is rapidly broken down in the body and thus not practical as a therapy for type 2 diabetes. Studies to date show that liraglutide significantly improves glycaemic control in monotherapy and in combination therapy with metformin.

The trial results do not affect Novo Nordisk's previous financial expectations for 2007.

Novo Nordisk said it would post results from the remaining two LEAD studies in H2 2007 and Q1 2008.

Novo Nordisk's CSO, Mads Krogsgaard Thomsen, said of the data: "The encouraging clinical results from the two new trials confirm the positive effect of Liraglutide and leave us confident that we are on track to submit for regulatory approval mid-2008."

20th August 2007

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Langland

Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...

Latest intelligence

dementia
Alzheimer’s Research UK highlights socio-economic inequalities in dementia risk
The charity aims to improve the number of women participating in dementia research and grow awareness of dementia risk factors...
Data security
Concerns about data security are building a strong case for clinical mobility in EMEA
Electronic medical records have transformed the storage of sensitive information but how can the healthcare sector continue to protect patient and staff data?...
Mainimage2
The role of digital health technology tools in supporting medical adherence
How DHT-based digital interventions can help to support patients and improve adherence...